Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11094354 | 0.85 | USP30 (0.47) | MEN1KMT2ACYP2D6DRD3USP30 | |
| SCHEMBL3370271 | 0.81 | MEN1 (0.49) | NAMPTMEN1KMT2APDE10AGSK3B | |
| SCHEMBL3373269 | 0.81 | MEN1 (0.49) | NAMPTMEN1KMT2APDE10AGSK3B | |
| SCHEMBL3372157 | 0.81 | MEN1 (0.49) | NAMPTMEN1KMT2APDE10AGSK3B | |
| SCHEMBL19049375 | 0.79 | MEN1 (0.46) | NAMPTMEN1KMT2APDE10AGSK3B | |
| SCHEMBL2294991 | 0.77 | GRIN2B (0.51) | NAMPTMEN1KMT2ACYP1A2MOGAT2 | |
| SCHEMBL2296318 | 0.77 | GRIN2B (0.51) | NAMPTMEN1KMT2ACYP1A2MOGAT2 | |
| SCHEMBL2296518 | 0.76 | PKM (0.45) | NAMPTMEN1KMT2APDE10AGSK3B | |
| SCHEMBL19002793 | 0.76 | MEN1 (0.46) | NAMPTMEN1KMT2AGSK3BCYP1A2 | |
| SCHEMBL19002802 | 0.76 | MEN1 (0.43) | NAMPTMEN1KMT2APDE10AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592417-B2 | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2097409-B1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-101652361-A | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORP | 2010-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, TTBK2 | NAMPT 1325/4885MEN1 3650/4885KMT2A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.